Abstracts tagged "proteomics"

Abstract Number: 0975 • ACR Convergence 2022
Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE
Paul Newcombe¹, Richard A. Furie², Yoshiya Tanaka³, Wendy White⁴, Dominic Sinibaldi⁴, Philip Brohawn⁴, Mark Lazarus¹, Nicola Ferrari¹, Raj Tummala⁴, Hussein Al-Mossawi¹, Andre Nogueria da Costa⁵, Daniel Muthas⁵ and Madhu Ramaswamy⁴, ¹AstraZeneca, Cambridge, United Kingdom, ²Northwell Health, Great Neck, NY, ³University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁴AstraZeneca, Gaithersburg, MD, ⁵AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE has been associated with expression of type I IFN gene signatures (IFNGS).1 Anifrolumab, a monoclonal antibody binding IFN receptor subunit 1, inhibits downstream…
Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Thierry Sornasse¹, Heidi Camp², Fang Cai³, Justin Klaff² and Iain McInnes⁴, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie, Redwood City, CA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…
Abstract Number: 1400 • ACR Convergence 2021
Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study
Karin Wadström¹, Jan-Åke Nilsson¹, Aladdin Mohammad², Kenneth Warrington³, Eric Matteson⁴, Magnus Jakobsson², Lennart Jacobsson⁵ and Carl Turesson⁶, ¹Lund University, Malmö, Sweden, ²Lund University, Lund, Sweden, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵University of Gothenburg, Gothenburg, Sweden, ⁶Lund University, Malm, Sweden
Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
Abstract Number: 1434 • ACR Convergence 2021
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
Victor Farutin¹, Elma Kurtagic², Joel Pradines³, Ishan Capila³, Maureen Mayes⁴, Minghua Wu⁵, Anthony Manning³ and Shervin Assassi⁶, ¹Janssen R&D, LLC, Watertown, MA, ²Janssen R&D, LLC, Cambridge, ³Momenta Pharmaceuticals, Inc., Cambridge, MA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵University of Texas Health Science Center at Houston, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Discovery of biomarkers in systemic sclerosis (SSc) represents an unmet clinical need. Samples from prominently affected fibrotic end-organs such as lung and skin are…
Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Thierry Sornasse¹, Jaclyn Anderson², Koji Kato³, Apinya Lertratanakul⁴, Christopher Ritchlin⁵ and Iain McInnes⁶, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc, Gurnee, IL, ³AbbVie Inc, Shinagawa- Ku, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…
Abstract Number: 1858 • ACR Convergence 2021
Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
Monique Hinchcliff¹, Suiyuan Huang², Shervin Assassi³, Elana Bernstein⁴, Flavia Castelino⁵, Robyn Domsic⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Ami Shah¹⁰, Victoria Shanmugam¹¹, Virginia Steen¹², Dinesh Khanna² and Francesco Del Galdo¹³, ¹Yale School of Medicine, Westport, CT, ²University of Michigan, Ann Arbor, MI, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Columbia University, New York, NY, ⁵Massachusetts General Hospital, Boston, MA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins Rheumatology, Baltimore, MD, ¹¹The George Washington University, Great Falls, VA, ¹²Division of Rheumatology, Georgetown University, Washington, DC, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Several published studies have demonstrated activation of the interferon type 1 (IFN) pathway in sera from patients with systemic sclerosis (SSc). Specifically, levels of…
Abstract Number: 0037 • ACR Convergence 2021
Identification and Validation of Four Circulating Autoantibodies Associated with the ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Cristina Ruiz-Romero², Lidia Collado¹, Monika Hansson³, Lars Klareskog⁴, Ronald Sjöberg⁵, Elisa Pin⁵, Peter Nilsson⁵ and Francisco Blanco-García⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España., A Coruña, Spain, ²Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11, 28029, Madrid, España., A Coruña, Spain, ³Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology & SciLifeLab, Stockholm, Sweden, ⁶Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España.Universidade da Coruña (UDC), Grupo de Investigación de Reumatología y Salud (GIR-S). Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, 15008, A Coruña, España., A Coruña, Spain
Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPAs) is a highly specific hallmark of rheumatoid arthritis (RA), that is present also in early disease. However,…
Abstract Number: 0051 • ACR Convergence 2021
Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid
Jacqueline Lai¹, Sara Rahmati², Raam Sivakumar², Katerina Oikonomopoulou³, Fatima Abji⁴ and Vinod Chandran⁵, ¹McMaster University, Hamilton, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
Abstract Number: 0434 • ACR Convergence 2021
Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis
Mikael Brink¹, Ewa Berglin¹, Aladdin Mohammad², Andrey Alexeyenko³, Kristina Lejon¹ and Solbritt Rantapaa-Dahlqvist⁴, ¹Umeå Universitet, Umeå, Sweden, ²Lund University, Lund, Sweden, ³Karolinska Institutet, Stockholm, Sweden, ⁴Ume University, Umea, Sweden
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is considered a chronic relapsing condition, with unknown etiology. This study was undertaken to gain insight to the…
Abstract Number: 0442 • ACR Convergence 2021
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Kenichi Uto¹, Koji Ueda², Takaichi Okano¹, Kengo Akashi¹, Soshi Takahashi³, Yuji Nakamachi⁴, Takamitsu Imanishi¹, Seiji Kawano¹, Yoshihiko Yano⁵ and Jun Saegusa⁶, ¹Kobe University Hospital, Kobe, Japan, ²Japanese Foundation for Cancer Research, Tokyo, Japan, ³Shinko Hospital, Kobe, Japan, ⁴Kobe University School of Medicine, Kobe, Japan, ⁵Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, ⁶Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
Abstract Number: 0449 • ACR Convergence 2021
Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
Orla Coleman¹, Bruna Wundervald², Ruoyi Zhou³, James Waddington³, Robert LJ Graham⁴, Ciaren Graham⁴, Geoff McMullan⁴, Andrew C. Parnell⁵, Vinod Chandran⁶, Philip Mease⁷, Gaia Gallo⁸, Venkatesh Krishnan⁸, Stephen Pennington⁹ and Oliver FitzGerald¹⁰, ¹Atturos, Bray, Ireland, ²Atturos, Maynooth, Ireland, ³Atturos, Belfield, Ireland, ⁴Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, ⁵Maynooth University, Maynooth, Ireland, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹University College Dublin, Dublin, Ireland, ¹⁰Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Asmaa AbuMaziad¹, Abhimanyu Amarnani² and Ram Singh³, ¹University of California Los Angeles, Los Angeles, CA, ²Los Angeles County + University of Southern California, Los Angeles, CA, ³University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Kristina Clark¹, Eszter Csomor², Corrado Campochiaro³, Adam Taylor⁴, Yee Voan Teo², Katherine Nevin², Mary Morse², Voon Ong⁵, Emma Derrett-Smith⁶, Nicolas Wisniacki², Shaun Flint² and Christopher Denton⁷, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ³Royal Free Hospital London, London, United Kingdom, ⁴GlaxoSmithKline, London, United Kingdom, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, London, United Kingdom, ⁷University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
Abstract Number: 0693 • ACR Convergence 2021
Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
Eleni Tiniakou¹, Andrew Mammen² and Erika Darrah¹, ¹Johns Hopkins University, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…
Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Fang Cai¹, Thierry Sornasse², Feng Hong³, Heidi Camp⁴, Koji Kato⁵ and Iain McInnes⁶, ¹AbbVie, Redwood City, CA, ²AbbVie Inc, Redwood City, CA, ³AbbVie, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].